<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311077</url>
  </required_header>
  <id_info>
    <org_study_id>HMR1964A_1502</org_study_id>
    <nct_id>NCT00311077</nct_id>
  </id_info>
  <brief_title>Insulin Glulisine in Healthy Lean and Obese Subjects</brief_title>
  <official_title>Pharmacodynamic and Pharmacokinetic Properties of Insulin Glulisine (Apidra) in Comparison to Insulin Lispro (Humalog) in Healthy Lean and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective

        -  To investigate pharmacodynamic and pharmacokinetic parameters after s.c. administration
           of two different doses (low dose, 0.2 IU/kg and high dose, 0.4 IU/kg) of insulin
           glulisine across healthy subjects in 4 different BMI-classes (lean, overweight,
           moderately obese, severely obese), using the euglycemic clamp technique with the
           Biostator™.

      Secondary objective

        -  To investigate the pharmacodynamic and pharmacokinetic properties after subcutaneous
           administration of insulin glulisine in comparison to insulin lispro and to investigate
           the safety and tolerability after subcutaneous administration of insulin glulisine in
           comparison to insulin lispro.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the serum insulin glulisine concentration and insulin lispro concentration</measure>
    <time_frame>During the Study Conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure blood glucose</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure glucose infusion rate</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the serum C-peptide</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>from the inform consent signed up to the end of the study</time_frame>
  </secondary_outcome>
  <condition>Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Normal HbA1c

          -  Women have to either be postmenopausal, surgically sterilized, or not pregnant and
             using adequate contraception.

        Exclusion criteria :

          -  Systemic concomitant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Pilorget, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2006</study_first_submitted>
  <study_first_submitted_qc>April 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2006</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

